1. Adult patient with severe, active and progressive rheumatoid arthritis (RA) .

2. Pediatric patient aged 2 years and older with active systemic juvenile idiopathic arthritis (sJIA)

3. Adult and pediatric patient aged 2 years and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).

SKU: TOLIZUFIX 80mg/ 4 mL (20 mg/mL) Concentrate for Solution for Infusion (IV) 4 mL VIAL 1
MOLECULE: Tocilizumab
THERAPEUTIC CLASS: Interleukin Inhibitor

FORMULATION:
Each vial contains:
Recombinant humanized anti-human IL-6R
monoclonal antibody ………… 80mg

Treatment should be initiated by Healthcare Professionals with experience in the diagnosis and treatment of RA, sJIA, pJIA or CRS.